Advanced Accelerator Applications is a radiopharmaceutical company, develops, produces, and commercializes radiolabeled pharmaceuticals and diagnostic nuclear medicines in France and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of oncology through assessing glucose metabolism; DOPAVIEW, a PET tracer for diagnostic use with applications in neurology and oncology sectors; and FluoroChol, a PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. In addition, it offers NETSPOT, a kit for the preparation of gallium Ga 68 dotatate injection for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using PET; SomaKit TOC, a kit for radiopharmaceutical preparation of gallium edotreotide solution; and Annexin V-128, a SPECT radiopharmaceutical product candidate for the imaging of apoptotic and necrotic lesions. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that has been approved for the treatment of neuro endocrine tumors; PSMA-R2, a selective PSMA-targeted ligand for prostate cancer; and NeoBOMB1, an antagonist bombesin analogue targeting GRPR-expressing malignancies. The company serves public and private hospitals, universities, third-party research laboratories, clinical centers, and pharmaceutical companies.